文献速递妇科

基于非靶向代谢组学的尼拉帕利耐药卵巢癌细胞代谢特征

[Metabolic signatures of niraparib-resistant ovarian cancer cells based on non-target metabolomics].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2025-01-01

以卵巢腺癌细胞株A2780为亲本,用浓度梯度递增法建立尼拉帕利耐药株A2780-NiraR,检测其生物学特性并用非靶向代谢组学分析差异代谢物。耐药株对尼拉帕利IC50为26.19 μmol/L,显著高于亲本株的3.17 μmol/L;筛选出44种差异代谢物,精氨酸代谢、嘌呤代谢和嘧啶代谢通路富集最显著。

要点

  • A2780-NiraR对尼拉帕利IC50为26.19 μmol/L,亲本A2780为3.17 μmol/L,差异有统计学意义(F=98.50,P<0.001)。
  • 耐药株倍增时间(37.5±1.9)h长于亲本株(14.5±1.0)h,S期比例降低、G0/G1期比例升高(P<0.001)。
  • 筛选出44种差异代谢物,精氨酸代谢、嘌呤代谢和嘧啶代谢通路富集最显著。

核心结论

  • A2780-NiraR细胞具有稳定的尼拉帕利耐药表型,精氨酸代谢等通路可能是增强卵巢癌尼拉帕利疗效的潜在治疗靶点。

研究设计与样本

  • 以卵巢腺癌细胞株A2780为亲本,采用体外阶段式浓度梯度递增诱导法建立尼拉帕利耐药细胞株A2780-NiraR。
  • 用倒置相差显微镜观察形态,细胞毒性实验测定IC50,CCK-8法和细胞直接计数法检测增殖,流式细胞仪分析细胞周期。
  • 采用基于超高效液相色谱/高分辨率质谱(UPLC/HRMS)的非靶向代谢组学筛选差异代谢物,并行KEGG通路富集分析。

主要发现

  • A2780-NiraR细胞形态以短梭形或卵圆形为主,突起变少,边界不清。
  • A2780-NiraR细胞对尼拉帕利的IC50为26.19 μmol/L,A2780细胞为3.17 μmol/L(F=98.50,P<0.001)。
  • A2780-NiraR细胞倍增时间为(37.5±1.9)h,长于A2780细胞的(14.5±1.0)h(t=10.50,P<0.001)。
  • A2780-NiraR细胞S期比例为(30.2±2.9)%,低于A2780细胞的(44.5±0.7)%;G0/G1期比例为(52.2±3.1)%,高于A2780细胞的(35.4±1.2)%(P<0.001)。
  • 基于OPLS-DA筛选出44种差异代谢物,A2780-NiraR细胞中吡咯烷酮羧酸、L-赖氨酸和1-吡咯啉-4-羟基-2-羧酸盐等显著增加,KEGG富集前3位为精氨酸代谢、嘌呤代谢和嘧啶代谢通路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To establish a niraparib-resistant ovarian cancer cell line and preliminarily explore its biological characteristics and metabolic signatures. Methods: (1) Using ovarian adenocarcinoma cell line A2780 as parental cells, the niraparib-resistant cell line A2780-NiraR was established by the method of concentration gradient increased induction, and its morphological characteristics were observed using inverted phase-contrast microscope. The half-inhibitory concentration (IC50) of niraparib was determined by cytotoxicity assay. (2) Cell proliferation was determined by cell count kit-8 (CCK-8) assay and direct cell counting assay, cell cycle distribution was analyzed by flow cytometry. (3) The differential metabolites between A2780 and A2780-NiraR cells were detected by non-target metabolomics based on ultra-high performance liquid chromatography-high resolution mass spectrometry (UPLC/HRMS). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was conducted on the above differential metabolites to explore related metabolic pathways. Results: (1) Compared with the parental A2780 cells, A2780-NiraR cells exhibited predominantly short-spindle or oval morphology with reduced cellular projections and indistinct cell borders. The IC50 values of niraparib were 3.17 and 26.19 μmol/L against A2780 cells and A2780-NiraR cells, respectively (F=98.50, P<0.001). (2) A2780-NiraR cells had a slower proliferation rate compared with A2780 cells (F=146.80, P<0.001). The doubling time of A2780-NiraR cells [(37.5±1.9) hours] was significantly longer than that of A2780 cells [(14.5±1.0) hours; t=10.50, P<0.001]. Compared with the parental A2780 cells, A2780-NiraR cells had a significantly lower S phase fraction [(44.5±0.7)% in A2780 cells, (30.2±2.9)% in A2780-NiraR cells; t=4.78, P<0.001] and higher G0/G1 phase fraction [(35.4±1.2)% in A2780 cells, (52.2±3.1)% in A2780-NiraR cells; t=5.10, P<0.001]. (3) The metabolites of A2780 and A2780-NiraR cells were analyzed by non-target metabolomics. Forty-four differential metabolites between A2780 and A2780-NiraR cells were screened using the orthogonal partial least squares-discriminant analysis (OPLS-DA) model, the majority of which were significantly increased, such as pyrrolidone carboxylic acid, L-lysine and 1-pyrroline-4-hydroxy-2-carboxylate. Pathway enrichment analysis indicated that the arginine metabolism, purine metabolism, and pyrimidine metabolism were the most significantly enriched pathways. Conclusion: A2780-NiraR cells have acquired a stable niraparib resistance phenotype, and metabolic pathways including arginine metabolism may serve as potential therapeutic targets for enhancing niraparib efficacy in ovarian cancer. 目的: 构建卵巢上皮性癌(卵巢癌)尼拉帕利耐药细胞株,初步探讨其生物学特性和代谢特征。 方法: (1)以卵巢癌细胞株A2780为亲本细胞,使用体外阶段式浓度梯度递增诱导法建立尼拉帕利耐药细胞株A2780-NiraR,并使用倒置相差显微镜观察A2780-NiraR细胞的形态特征,采用细胞毒性实验测定A2780-NiraR细胞对尼拉帕利的50%抑制浓度(IC50)。(2)通过活细胞计数(CCK-8)法、细胞直接计数法、流式细胞仪检测A2780-NiraR细胞的生物学特性。(3)采用基于超高效液相色谱/高分辨率质谱(UPLC/HRMS)检测的非靶向代谢组学技术筛选A2780细胞与A2780-NiraR细胞的差异代谢物,并行京都基因和基因组百科全书(KEGG)信号通路富集分析探究差异代谢物相关的信号通路。 结果: (1)与亲本细胞A2780比较,尼拉帕利耐药的A2780-NiraR细胞的形态以短梭形或卵圆形为主,突起变少,边界不清。A2780、A2780-NiraR细胞对尼拉帕利的IC50分别为3.17和26.19 μmol/L,两者比较,差异有统计学意义(F=98.50,P<0.001)。(2)A2780-NiraR细胞的增殖速度较A2780细胞显著变慢(F=146.80,P<0.001);A2780-NiraR细胞的倍增时间为(37.5±1.9)h,显著长于A2780细胞的(14.5±1.0)h(t=10.50,P<0.001)。A2780-NiraR细胞的S期细胞比例为(30.2±2.9)%,显著低于A2780细胞的(44.5±0.7)%(t=4.78,P<0.001);G0/G1期细胞比例为(52.2±3.1)%,显著高于A2780细胞的(35.4±1.2)%(t=5.10,P<0.001)。(3)采用非靶向代谢组学技术解析A2780和A2780-NiraR细胞的代谢物水平,基于正交偏最小二乘法-判别分析(OPLS-DA)筛选出A2780-NiraR细胞与A2780细胞的44种差异代谢物,其中在A2780-NiraR细胞中吡咯烷酮羧酸、L-赖氨酸和1-吡咯啉-4-羟基-2-羧酸盐等代谢物的含量显著增加;KEGG信号通路富集分析排序在前3位的信号通路为精氨酸代谢通路、嘌呤代谢通路和嘧啶代谢通路。 结论: A2780-NiraR细胞有稳定的尼拉帕利耐药性,精氨酸代谢等信号通路可能是导致卵巢癌尼拉帕利耐药的潜在靶途径。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lin H, Jin HY, Lyu WG, et al. [Metabolic signatures of niraparib-resistant ovarian cancer cells based on non-target metabolomics]. Zhonghua Fu Chan Ke Za Zhi. 2025. PMID: 40854746. doi:10.3760/cma.j.cn112141-20250113-00023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。